Synthesis of 8-chloro-5,5-dioxo[1,2,4]triazolo[4,3-b][1,4,2]benzodithiazine derivatives with potential anticancer and anti-HIV-1 activities

Polish Journal of Chemistry

Volumn 79, Issue 10, 2005, Pages 1659-1666

  Brzozowski, Z ^a   Saczewski F ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

8 chloro 5,5 dioxo 1,2,4 triazolo 4,3 b 1,4,2 benzodithiazines; Antitumor and anti HIV 1 activities; Synthesis

Indexed keywords

EID: 27144456185     PISSN: 01375083     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Casini A., Scozzafova A., Mastrolorenzo A. and Supuran C.T., Curr. Cancer Drug Targets, 2, 55 (2002).
2. Scozzafova A., Owa T., Mastrolorenzo A. and Supuran C.T., Curr. Med. Chem., 10, 925 (2003).
3. Supuran C.T., Casini A. and Scozzafova A., Med. Res. Rev., 23, 531 (2003).
4. Sławiński J., Bednarski P., Grünert R. and Reszka P., Polish J. Chem., 77, 53 (2003).
5. Sławiński J., Eur. J. Med. Chem., 39, 179 (2003).
6. Sławiński J., Bednarski P. and Reszka P., Polish J. Chem., 78, 369 (2004).
7. Brzozowski Z., Acta Polon. Pharm Drug Res., 55, 375 (1998).
8. Brzozowski Z., Acta Polon. Pharm. Drug Res., 55, 473 (1998).
9. Pomarnacka E., Acta Polon. Pharm. Drug Res., 55, 481 (1998).
10. Kuo C.L., Assefa H., Kamath S., Brzozowski Z., Sławiński J., Sa̧czewski F., Buolamwini J.K. and Neamati N., J. Med. Chem., 47, 385 (2004).
11. Neamati N., Mazumder A., Sunder S., Owen J.M., Schultz R.I. and Pommier Y., Antiviral Chem. Chemother., 8, 485 (1997).
12. Brzozowski Z., Acta Polon. Pharm. Drug Res., 54, 293 (1997).
13. Brzozowski Z., Sa̧czewski F., Sanchez T., Kuo C.L., Gdaniec M. and Neamati N., Bioorg. Med. Chem., 12, 3663 (2004).
14. Brzozowski Z. and Sa̧czewski F., J. Med. Chem., 45, 430 (2002).
15. Pomarnacka E. and Gdaniec M., Bioorg. Med. Chem., 11, 1259 (2003).
16. Brzozowski Z., Sa̧czewski F. and Gdaniec M., Bioorg. Med. Chem., 11, 3737 (2003).
17. Brzozowski Z., Sa̧czewski F. and Gdaniec M., Eur. J. Med. Chem., 38, 991 (2003).
18. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vagiro-Wolff A., Gray-Goodrich M., Campell H., Mayo J. and Boyd M., J. Natl. Cancer Inst., 83, 757 (1991).
19. Grever M.R., Schepartz S.A. and Chamber B.A., The National Cancer Institute: Cancer Drug Discovery and Development Program. Semin. Oncol., 19, 622 (1992).
20. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornanance A.J., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., Osdol W.W., Monks A.P., Scudiero D.A., Sausiville E.A., Zaharevitz D.W., Bunow B., Viswanadhan V.N., Jonson G.S., Wittes R.E. and Paull K.D., Science, 275, 343 (1977).
21. Wieslow O.W., Kiser R., Fine D., Bader J., Shoemaker R.H. and Boyd M.R., J. Natl. Cancer Inst., 81, 577 (1989).
22. Brzozowski Z., Acta Polon. Pharm. Drug. Res., 53, 269 (1996).
23. Pomarnacka E., Acta Polon. Pharm. Drug Res., 53, 373 (1996).
24. Pomarnacka E. and Brzozowski Z., Acta Polon. Pharm. Drug Res., 54, 215 (1997).